Oxytrol® (oxybutynin) – Updated indication
October 24, 2017 – The FDA approved an update to the Indications section of the Oxytrol (oxybutynin) transdermal system drug label, for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency.
Download PDF
